{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:39:04Z","timestamp":1759412344752},"reference-count":46,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["400894\/2014-9"],"award-info":[{"award-number":["400894\/2014-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.03.020","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T04:17:33Z","timestamp":1522124253000},"page":"2480-2486","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis"],"prefix":"10.1016","volume":"36","author":[{"given":"Izabella","family":"Pereira Silva Bezerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Amaral Abib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartira","family":"Rossi-Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.03.020_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.020_b0010","doi-asserted-by":"crossref","unstructured":"GBD 2015. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet; 2016. http:\/\/doi.org\/10.1016\/S0140-6736(16)31678-6.","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"10.1016\/j.vaccine.2018.03.020_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005739","article-title":"A new perspective on cutaneous leishmaniasis \u2013 Implications for global prevalence and burden of disease estimates","author":"Bailey","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2018.03.020_b0020","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.020_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1777-x","article-title":"Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery","author":"Mendon\u00e7a","year":"2016","journal-title":"Parasit Vectors"},{"issue":"28","key":"10.1016\/j.vaccine.2018.03.020_b0030","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.020_b0035","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1590\/S0074-02762002000700019","article-title":"Study of the safety, immunogenicity and efficacy of attenuated and killed leishmania (Leishmania) major Vaccines in a Rhesus Monkey (Macaca mulatta) Model of the Human Disease","volume":"97","author":"Amaral","year":"2002","journal-title":"Mem Inst Oswaldo Cruz Rio Janeiro"},{"key":"10.1016\/j.vaccine.2018.03.020_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.trstmh.2005.04.002","article-title":"Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia","author":"V\u00e9lez","year":"2005","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.03.020_b0045","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.163.8.4481","article-title":"Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis","volume":"163","author":"Kenney","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(03)00427-4","article-title":"Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB\/c and C57BL\/6 mice against cutaneous leishmaniasis","author":"Pinto","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.020_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2005.04.016","article-title":"TGF-\u03b2-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens","author":"Pinheiro","year":"2005","journal-title":"Microbes Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2018.03.020_b0060","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.4049\/jimmunol.138.12.4450","article-title":"Distinctive cellular immunity in genetically susceptible BALB\/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites","volume":"138","author":"Liew","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061296","article-title":"Cutaneous manifestations of human and murine leishmaniasis","author":"Scorza","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2018.03.020_b0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1074-7613(00)80342-8","article-title":"IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB\/c mice","volume":"6","author":"Launois","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.03.020_b0075","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.4049\/jimmunol.165.10.5637","article-title":"Priming by microbial antigens from the intestinal flora determines the ability of CD4(+) T cells to rapidly secrete IL-4 in BALB\/c mice infected with Leishmania major","volume":"165","author":"Julia","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.274.5286.421","article-title":"Resistance to Leishmania major induced by tolerance to a single antigen","volume":"274","author":"Julia","year":"1996","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2018.03.020_b0085","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/intimm\/6.10.1535","article-title":"Intravenous injection of irradiated Leishmania major into susceptible BALB\/c mice: immunization or protective tolerance","volume":"6","author":"Aebischer","year":"1994","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0090","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.72.8.4521-4527.2004","article-title":"Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK","author":"Pinto","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.03.020_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1822-9","article-title":"Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl\/6 mice","author":"Pratti","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2018.03.020_b0100","unstructured":"Da Silva-Couto L, Peralva Ribeiro-Rom\u00e3o R, Saavedra AF, Lilian B, Silva D, Souza C, et al. Intranasal vaccination with leishmanial antigens protects golden hamsters (Mesocricetus auratus) Against Leishmania (Viannia) braziliensis Infection. PLoS Negl Trop Dis; 2015. 9797103111. http:\/\/doi.org\/10.1371\/journal.pntd."},{"key":"10.1016\/j.vaccine.2018.03.020_b0105","doi-asserted-by":"crossref","DOI":"10.1017\/S0031182015001250","article-title":"Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB\/c mice challenged with Leishmania (infantum) chagasi","author":"Leal","year":"2015","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2018.03.020_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/0001-706X(95)00128-2","article-title":"Therapeutic effect of oral Kalanchoe pinnata leaf extract in murine leishmaniasis","author":"Da Silva","year":"1995","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2018.03.020_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/laban0511-155","article-title":"Retro-orbital injections in mice","author":"Yardeni","year":"2011","journal-title":"Lab Anim (NY)"},{"key":"10.1016\/j.vaccine.2018.03.020_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00108-17","article-title":"Not all antigens are created equally: progress, challenges, and lessons associated with developing a vaccine for leishmaniasis","author":"Duthie","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.00467","article-title":"Post-genomics and vaccine improvement for Leishmania","author":"Seyed","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1590\/S0074-02761998000200014","article-title":"Phase 1 Study of an inactivated vaccine against American Tegumentary Leishmaniasis in normal volunteers in Brazil","volume":"93","author":"Marzochi","year":"1998","journal-title":"Mem Inst Oswaldo Cruz Rio Janeiro"},{"key":"10.1016\/j.vaccine.2018.03.020_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(98)00338-7","article-title":"Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis","author":"De Luca","year":"1999","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.020_b0140","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4049\/jimmunol.135.3.2095","article-title":"Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection","volume":"135","author":"Liew","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0145","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.4049\/jimmunol.135.3.2108","article-title":"Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically susceptible BALB\/c mice","volume":"135","author":"Titus","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0150","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.4049\/jimmunol.136.8.3067","article-title":"Prophylactic treatment of BALB\/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major","volume":"136","author":"Behforouz","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0001-706X(94)90045-0","article-title":"Effect of in vivo depletion Of CD4+ T cells on experimental infection of susceptible Balb\/C mice with Leishmania amazonensis","volume":"56","author":"Howard","year":"1994","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2018.03.020_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/nri.2016.36","article-title":"Development and maintenance of intestinal regulatory T cells","author":"Tanoue","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0165","doi-asserted-by":"crossref","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","author":"Marques-Da-Silva","year":"2005","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2018.03.020_b0170","article-title":"Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis","author":"Gomes","year":"2012","journal-title":"Parasitology"},{"issue":"33","key":"10.1016\/j.vaccine.2018.03.020_b0175","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1016\/j.vaccine.2010.04.109","article-title":"Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine","volume":"28","author":"de Matos Guedes","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.020_b0180","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.4049\/jimmunol.174.11.7147","article-title":"CD4 + CD25 + Regulatory T Cells Restrain pathogenic responses during Leishmania amazonensis infection","volume":"174","author":"Ji","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-7-70","article-title":"Leishmania braziliensis and Leishmania amazonensis amastigote extracts differ in their enhancement effect on Leishmania infection when injected intradermally","author":"De-Araujo","year":"2014","journal-title":"BMC Research Notes"},{"key":"10.1016\/j.vaccine.2018.03.020_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1720827","article-title":"Regulatory T cells: molecular actions on effector cells in immune regulation","author":"Arce-Sillas","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2018.03.020_b0195","article-title":"Intranasal delivery of E-selectin reduces atherosclerosis in ApoE-\/- mice","author":"Li","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.020_b0200","doi-asserted-by":"crossref","DOI":"10.1111\/cei.12726","article-title":"Intranasal immunization with heat shock protein 60 induces CD4 1 CD25 GARP 1 and type 1 regulatory T cells and inhibits early atherosclerosis","author":"Zhong","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.020_b0205","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4049\/jimmunol.181.2.899","article-title":"Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes","volume":"181","author":"Broere","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.1214935","article-title":"Disease tolerance as a defense strategy","author":"Medzhitov","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.03.020_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00278-09","article-title":"Intranasal vaccinations with the trans-sialidase antigen plus CpG adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges","author":"Giddings","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.03.020_b0220","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00263-13","article-title":"Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin","author":"Carapau","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.03.020_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2013.48","article-title":"Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines","author":"Nacer","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.03.020_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-015-0636-5","article-title":"Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice","author":"Zhang","year":"2015","journal-title":"Parasit Vectors"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:09:41Z","timestamp":1693598981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18303566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":46,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18303566"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}